share_log

RBC Capital Maintains Outperform on Karuna Therapeutics, Raises Price Target to $293

RBC Capital Maintains Outperform on Karuna Therapeutics, Raises Price Target to $293

加拿大皇家银行资本维持Karuna Therapeutics的跑赢大盘,将目标股价上调至293美元
Benzinga Real-time News ·  2022/09/29 07:14

RBC Capital analyst Brian Abrahams maintains Karuna Therapeutics (NASDAQ:KRTX) with a Outperform and raises the price target from $292 to $293.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发